Welcome to our dedicated page for Incannex Healthcare news (Ticker: IXHL), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.
Incannex Healthcare Inc. reports company developments tied to its clinical-stage combination therapy pipeline, Nasdaq listing status and capital actions. Recurring updates describe IHL-42X, its oral fixed-dose combination program for obstructive sleep apnea, including clinical development strategy, sleep-medicine research partnerships and FDA Fast Track Designation.
News also covers PSX-001, the company’s oral synthetic botanical research compound formulation for generalized anxiety disorder, along with balance-sheet commentary, share repurchase activity, reverse stock split disclosures and Nasdaq minimum bid price compliance. The company’s communications generally center on clinical progress, regulatory context, financing capacity and public-company capital structure.
Incannex Healthcare (Nasdaq: IXHL) reported that the first patient has been dosed in DReAMzz, its Phase 2 crossover dose-optimization study of IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea (OSA). All 14 U.S. trial sites have Institutional Review Board approval, drug product has been manufactured, and patient screening is underway.
According to Incannex, IHL-42X previously showed statistically significant reductions in apnea-hypopnea index (AHI) versus placebo in the Phase 2 RePOSA study, with individual AHI reductions up to 83% and an exceptional safety profile. IHL-42X has received FDA Fast Track designation, and DReAMzz is intended to refine dose selection and support a planned Phase 3 program.
Incannex Healthcare (Nasdaq: IXHL) has received a final A$5,102,788.30 refund under the Australian Government’s R&D Tax Incentive Program, following approval of its overseas findings and amendment of its FY25 income tax return.
Combined with the previously announced A$6,039,162.43 refund, Incannex has now secured more than A$11.2 million in non-dilutive capital during 2026. According to the company, the proceeds, received without issuing equity or taking on debt, further strengthen its cash position and debt-free balance sheet, support advancement of key clinical assets such as IHL-42X and PSX-001, and align with its shareholder-focused capital allocation strategy. Incannex also expects additional R&D tax funding in 2027 for eligible ongoing activities.
Incannex Healthcare (Nasdaq: IXHL) has commenced participant screening in its DReAMzz Phase 2 randomized crossover dose-confirmation study of IHL-42X for obstructive sleep apnea (OSA). Initial clinical sites are approved and actively screening, with additional sites to begin as regulatory permissions are obtained.
IHL-42X has FDA Fast Track designation, enabling more frequent FDA interactions and a potentially expedited review pathway. The DReAMzz study is designed to optimize dosing and assess both objective sleep metrics and patient-reported outcomes, building on earlier Phase 2 data that showed up to 83% reduction in Apnea-Hypopnea Index, significant improvements in fatigue and sleep-related impairment, and a favorable safety profile. OSA affects an estimated one billion people globally, and there are currently no FDA-approved oral pharmaceutical therapies for this condition.
Incannex (Nasdaq: IXHL) received a U.S. patent for IHL-42X, a proprietary oral combination therapy for obstructive sleep apnea (OSA). The patent, titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea,” covers composition and therapeutic methods with a baseline expiry of 9 July 2040.
According to Incannex, this grant strengthens its lead clinical asset, complements FDA Fast Track status and positive Phase II data, and supports the ongoing DReAMzz Phase 2 dose-optimisation study ahead of a planned Phase III program.
Incannex (Nasdaq: IXHL) received A$6,039,162.43 under the Australian R&D Tax Incentive Program and expects about A$5.1 million more in 2026, for over A$11.1 million total non-dilutive funding.
The funds strengthen its debt‑free balance sheet and support clinical programs such as IHL-42X and PSX-001, plus its active share repurchase program.
Incannex (Nasdaq: IXHL) announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and a US$18.00 price target, in a report dated June 8, 2026 by analyst James Molloy.
The coverage evaluates Incannex’s clinical pipeline, including IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder, and is expected by the company to broaden investor awareness. AGP has received compensation from Incannex for investment banking services.
Incannex Healthcare (Nasdaq: IXHL) has officially commenced its DReAMzz clinical study of IHL-42X for obstructive sleep apnea (OSA). The crossover dose-optimization trial uses 14 clinical sites, with drug manufacturing, permits, and global distribution logistics in place.
The study aims to refine dosing and de-risk a planned Phase III program, building on positive Phase II RePOSA results and supported by FDA Fast Track designation for IHL-42X in OSA.
Incannex Healthcare (Nasdaq: IXHL) won the MedTech Breakthrough “Best New Technology Solution for Drug Development” award for its lead candidate IHL-42X, an oral combination therapy for obstructive sleep apnea (OSA).
According to Incannex, Phase 2 data showed statistically significant AHI reductions and improved oxygenation, sleep quality, and fatigue.
Incannex Healthcare (Nasdaq: IXHL) says its oral synthetic psilocybin program PSX-001 for Generalized Anxiety Disorder aligns with the White House Executive Order dated April 18, 2026. The company cites Phase 2 results showing a 12.8-point HAM-A reduction vs 3.6 placebo, 44% response and 27% remission in 73 patients.
Incannex reports no serious adverse events, an active U.S. IND, and over $70 million cash with no debt. The Executive Order could speed regulatory pathways but requires Phase 3 success for DEA rescheduling.
Incannex Healthcare (Nasdaq: IXHL) has reactivated its previously approved share repurchase program and executed repurchases over the past two trading days. The Board cited a belief that market valuation understates the company’s balance sheet, clinical progress, and future potential.
The company reported approximately $75 million in cash and no debt after recent financing, and stated that about $18.5 million remained available for repurchases as of December 31, 2025. The program is discretionary and may be modified, suspended, or discontinued.